TRS receives FDA approval for Cranial Bone Void Filler product

NewsGuard 100/100 Score

Tissue Regeneration Systems, Inc. ("TRS") today announced that it has received 510K approval from the U.S. Food and Drug Administration for its Cranial Bone Void Filler product, indicated for use in the repair of neurosurgical burr holes. This is first of a family of craniomaxillofacial surgery products being developed by TRS that incorporate the company's novel skeletal reconstruction and bone regeneration technology platform.

The 510K approval process required TRS to meet a high standard of pre-clinical testing and successfully pass a rigorous review by the FDA. "This is a significant milestone for the company," said Jim Fitzsimmons, president and chief executive officer. "With our base material and manufacturing processes now cleared by FDA, the approval pathway for future products can be streamlined," he added. TRS has filed a 510K for its second product, which is currently being reviewed by FDA. Other submissions are in work, according to Fitzsimmons. 

Applying a technology platform created at the Universities of Michigan and Wisconsin, TRS is developing advanced skeletal reconstruction implants with unique attributes. They are bioresorbable over time, fully replacing themselves with natural bone. Although their micro-architecture is porous to facilitate bone integration, they can bear load and they are strong enough to support function without need for reinforcement with metal plates. This structural integrity allows them to be used as an alternative to bone harvested from the patient for complex skeletal reconstruction. Using input from patient CT scans, their geometry can be custom constructed. Finally, they are integrated with a proprietary, osteoconductive coating that serves as an excellent substrate for adhesion and local, controlled release of growth factors to enhance bone regeneration.

"To our knowledge, this is first FDA approval of a coated bioresorbable skeletal reconstruction implant fabricated by means of 3D printing," said Fitzsimmons.  "This technology is definitely the wave of the future," he added.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How residential green spaces impact bone health and osteoporosis risk